Clera home
·Dashboard

Jobs at CRISPR Therapeutics (Now Hiring) — 4 open

CRISPR Therapeutics logoCRISPR Therapeutics

Scientist II, in vivo Gene Insertion

San Francisco, California, United States · On-site

$130k–$140k/yr

Mid level$957M raised

Job Description: Company Overview Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company ha…

Skills: Gene Editing, Synthetic Immunology, Molecular Biology, Cloning, Primary T Cell Culturing

CRISPR Therapeutics logoCRISPR Therapeutics

Senior Scientist, Analytical Development

Boston, Massachusetts, United States · On-site

$140k–$155k/yr

Senior+$957M raised

Job Description: Company Overview Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company ha…

Skills: Cell-based Assay Development, Flow Cytometry, Technology Transfer, Potency Assays, Mammalian Cell Culture

CRISPR Therapeutics logoCRISPR Therapeutics

Associate Director, Regulatory Affairs CMC

Boston, Massachusetts, United States · Hybrid

$165k–$180k/yr

Senior+$957M raised

Job Description: Company Overview Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company ha…

Skills: Regulatory CMC, Biologics, Cell and Gene Therapy, FDA Regulations, EMA Regulations

CRISPR Therapeutics logoCRISPR Therapeutics

Scientist II, LNP

Boston, Massachusetts, United States · On-site

$130k–$140k/yr

Mid level$957M raised

Job Description: Company Overview Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company ha…

Skills: Lipid Nanoparticle Design, LNP Formulation, Nanoparticle Characterization, Bioconjugation Chemistry, Nucleic Acid Encapsulation

CRISPR Therapeutics logo

Scientist II, in vivo Gene Insertion

CRISPR Therapeutics

San Francisco, California, United States • On-site

Apply
Mid level

Tired of cold applications?

Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.

  • $130k–$140k/yr
  • Full-time
  • postgraduate degree
  • Bonus, Equity
  • Posted 3d ago
  • ~40 hrs/week

Responsibilities

The role involves designing and executing workflows for in vivo gene insertion across various tissue and cell types. Responsibilities include developing editing and delivery strategies, performing quantitative assays, and collaborating cross-functionally to advance therapies toward clinical readiness.

Requirements

Candidates must have extensive experience in gene editing and synthetic immunology, with a PhD and 2-5+ years of experience or a non-PhD with 10-12+ years of experience. Proficiency in cloning, flow cytometry, and primary T cell culture is essential.

Full job description

Job Description:

Company Overview

Founded over a decade ago, CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. The Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics is advancing a broad and diversified pipeline across hemoglobinopathies, cardiovascular, autoimmune, oncology, regenerative medicine and rare diseases. The Company continues to expand its leadership in gene editing through the development of SyNTase™ editing, a novel and proprietary gene-editing platform designed to enable precise, efficient, and scalable gene correction. To accelerate and expand its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Position Summary

We are seeking highly motivated, talented, and independent researchers to grow our diverse, innovation-focused CRISPR-X team that pioneers novel in-vivo gene editing therapies for human disease. As part of CRISPR Therapeutics, a leading gene editing company, the candidate will be focused on working with our team on developing and enabling in vivo gene insertion across multiple tissue and cell types, with the goal of advancing cutting-edge in-vivo gene editing modalities across a range of different disease indications. The successful candidate will be comfortable working with different gene editing systems, possess a strong immunology and/or synthetic immunology background, and is comfortable moving into new areas of biology as needed. The position requires enthusiasm, adaptability, attention to detail, and a desire to create new medicines for patients.

Responsibilities

  • Design and execute workflows of conceive, build, and assess in primary cells

    • Requires extensive hands-on knowledge of molecular biology strategies, including advanced cloning methods, experience in handling various primary cell types (including T cells), familiarity with delivery strategies from transfection to viral transduction to novel targeted LNP (tLNP) approaches.

    • Strong sense of teamwork. Collaborate with various groups within CRISPR Tx and outside vendors to advance projects from both an editing and delivery perspective, with the ultimate goal of clinical readiness.

    • Extensive experience in quantitative biology. Iterate on assessing editing efficiency/gene insertion, impact on cell phenotype/construct expression, and ideation of new strategies.

  • Design and execute ddPCR assays to quantify transgene integration efficiency

  • Design and execute T cell phenotyping assays such as multicolor flow cytometry panels

  • Leverage immunology and/or synthetic immunology background to drive innovative editing, delivery, and expression strategies

  • Work cross-functionally to assess editing outcomes in animal models

  • Analyze and present experimental data to a wide range of audiences

  • Generate, manage, evaluate, and maintain critical data in a highly organized manner, providing statistical analysis and troubleshooting where appropriate

.

Minimum Qualifications

  • Extensive prior experience with gene editing and synthetic immunology in an academic and/or industry setting, with a track record demonstrating significant contributions.

  • Depending on level, degrees in Biology, Immunology, Genetics, Bioengineering, or related disciplines (level commensurate with experience and achievement):

    • Scientist II - PhD with minimum of 2-5+ years relevant experience; non-PhD with 10-12+ years progressive, relevant experience

  • Excellent technical skills for cloning, flow cytometry, primary T cell culturing, editing assays, and assessment of T cell phenotype and function

  • Experience managing multiple projects and priorities; ability to jump in to help other projects as needed

  • Strong communicator with a demonstrated record of being a highly collaborative team player within and across multiple departments

Preferred Qualifications

  • Knowledge and experience with in vivo delivery modalities such as tLNP, AAV, VLP, and others

  • Knowledge and experience with developing novel editing modalities

Competencies

  • Collaborative – Openness, One Team

  • Undaunted – Fearless, Can-do attitude

  • Results Orientation – Delivering progress toward our mission. Sense of urgency in solving problems.

  • Entrepreneurial Spirit – Proactive. Ownership mindset.

Due to the nature of their work, our manufacturing and lab-based positions are located fully on-site.

Scientist II: Base pay range of $130,000 to $140,000+ bonus, equity and benefits

The range provided is CRISPR Therapeutics’ reasonable estimate of the base compensation for this role. The actual amount will be based on job-related and non-discriminatory factors such as experience, training, skills, and abilities.

Pursuant to the San Francisco Fair Chance Ordinance, we will consider for employment qualified applicants with arrest and conviction records.

CRISPR Therapeutics, Inc. is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law.

To view our Privacy Statement, please click the following link: http://www.crisprtx.com/about-us/privacy-policy

Related keywords

CRISPRGene EditingIn VivoSynthetic ImmunologyT CellsLNPtLNPAAVVLPddPCRFlow CytometryMolecular BiologyBiopharmaceuticalGene InsertionPhenotypingTransduction

About CRISPR Therapeutics

LinkedInVisit site
Industry
Biotechnology Research
Company size
201-500 employees
Founded
2013
Headquarters
Boston, MA
LinkedIn followers
112,243
Total funding
$957M

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Offices: 105 West First Street, Boston, MA 02127, US · Baarerstrasse 14-16, Zug, CH CH-6300, CH · 90 Fetter Lane, London, England EC4A 1JP, GB · 455 Mission Bay Blvd S, San Francisco, California 94158, US

Gene EditingHematologyand Immuno-OncologyBiopharmaBiotechnologyGeneticsMedical
View all jobs at CRISPR Therapeutics

About CRISPR Therapeutics

LinkedInVisit site
Industry
Biotechnology Research
Company size
201-500 employees
Founded
2013
Headquarters
Boston, MA
LinkedIn followers
112,243
Total funding
$957M

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

Offices: 105 West First Street, Boston, MA 02127, US · Baarerstrasse 14-16, Zug, CH CH-6300, CH · 90 Fetter Lane, London, England EC4A 1JP, GB · 455 Mission Bay Blvd S, San Francisco, California 94158, US

Gene EditingHematologyand Immuno-OncologyBiopharmaBiotechnologyGeneticsMedical
View all jobs at CRISPR Therapeutics

Similar companies hiring

Thermo Fisher Scientific (2288)Roche (1155)CSL (966)Amgen (859)ICON plc (736)Syneos Health (398)Mineralys Therapeutics, Inc. (314)Fortrea (255)Agilent Technologies (243)Gilead Sciences (200)BeiGene (166)Genentech (162)
Clera home

Your AI-talent agent. Connecting talents with dream jobs.

Earn $5,000

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

Tools

  • Salary Calculator
  • Resume Review
  • Startup Map

Explore

  • Jobs
  • Discover Jobs
  • Companies
  • Referral

Platform

  • Pricing
  • Integrations
  • Partners
  • Acquihire

Clera

  • Manifesto
  • Engineering
  • We are hiring!
  • FAQs
  • Blog
  • Press

© 2026 Clera Labs, Inc.

PrivacyTermsBug Bounty